Thursday March 15, 2001 07:01 AM
Company Press Release
SOURCE:Nanogen, Inc.
Nanogen Begins Beta Testing of its NanoChip(TM) Molecular Biology Workstation For Targeted Gene Expression Applications
Also Announces 384 Well Plate Capability for Increased Automation
SAN DIEGO, March 15 /PRNewswire/ -- Nanogen, Inc. (Nasdaq: NGEN), producer of the only commercially available system for electronically controlled DNA reactions on microchips, announced today that it has entered into agreements with three institutions to begin beta testing of its NanoChip(TM) Molecular Biology Workstation for targeted gene expression applications. Two of the institutions have already begun gene expression beta tests and the third will start within the next two weeks. Two of the institutions are in the United States and one is in Europe.
Nanogen selected the institutions based on the quality of their research in the expression of individual genes and groups of genes related to cancer, neurological disorders, diabetes and other diseases, and on their experience with using various competitive gene expression technologies. The Company plans to utilize the data, results and feedback from the beta tests to increase the versatility of the NanoChip(TM) System by allowing researchers to use the system for gene expression applications in addition to the applications for which the system is currently sold, namely the detection and analysis of single nucleotide polymorphisms (SNPs), short tandem repeats (STRs) and hard-to-score mutations. Unlike most commercial gene expression techniques, Nanogen's is designed for scientists needing quantitative, reproducible assays with a known set of genes. These scientists will be looking for the capability to perform time-series studies with multiple samples on a single chip or across multiple chips.
Nanogen also announced that it has expanded the capability of the NanoChip(TM) System by upgrading its Loader to utilize either a 384 well plate or a 96 well plate. The larger 384 well plate is designed to improve productivity in the lab by increasing unattended automation and throughput.
jedoch Volumen fällt schon wieder,trotzdem über die 13 Tagelinie gelaufen,wird vermutlich leicht konsolidieren